Rafael pharma says 100 patients enrolled in pivotal phase 3 trial of cpi-613

Rafael pharmaceuticals reaches milestone of 100 patients enrolled in pivotal phase 3 trial (avenger 500) of cpi-613®️ (devimistat) for patients with metastatic pancreatic cancer.rafael pharmaceuticals reaches milestone of 100 patients enrolled in pivotal phase 3 trial (avenger 500) of cpi-613®️ (devimistat) for patients with metastatic pancreatic cancer.
RFL Ratings Summary
RFL Quant Ranking